Could a Half-Dose strategy prevent bone loss after stopping osteoporosis meds?

NCT ID NCT07281586

Recruiting now Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a gradual reduction of denosumab (Prolia) combined with zoledronic acid (Aclasta) can prevent bone loss after long-term osteoporosis treatment. 44 postmenopausal women and men over 50 who have taken denosumab for at least 3 years will be randomly assigned to either standard care or a de-escalation approach. The goal is to see if the new strategy better preserves bone density in the spine over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: denosumab (half-dose) and zoledronic acid
What this could lead to: If it works, this could offer a safer way to stop long-term osteoporosis treatment without losing bone density.
What could go wrong: This is a small, early-phase trial with only 44 people, so results may not apply to everyone. The de-escalation strategy might not prevent bone loss as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS

Contacts and locations

Locations

National Taiwan University Hospital Yunlin Branch
RECRUITING

Douliu, Taiwan, 640, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.